Seikagaku Announces New Drug Application Approval of HERNICORE 1.25 Units for Intradiscal Injection in Japan, Indicated for Treatment of Lumbar Disc Herniation.
Seikagaku Announces New Drug Application Approval of HERNICORE 1.25 Units for Intradiscal Injection in Japan, Indicated for Treatment of Lumbar Disc Herniation.
03.23.2018
This link will direct you to a third-party site.(Another window opens.)
The Seikagaku Corporation website uses cookies to personalize contents and offer a better browsing experience. Please click the Accept botton. (Read more)